{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T17:24:10Z","timestamp":1772213050832,"version":"3.50.1"},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["Gilead IN-US-334-1329."],"award-info":[{"award-number":["Gilead IN-US-334-1329."]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Direct-acting antiviral (DAA) drugs have been effective in the treatment of chronic hepatitis C virus (HCV) infection. Limited data are available on safety, tolerability, and efficacy in American Indian or Alaska Native people. We aim to evaluate the treatment outcomes of sofosbuvir- based regimens for treatment of HCV in a real life setting in Alaska Native\/American Indian (AN\/AI) people.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>AN\/AI patients within the Alaska Tribal Health System with confirmed positive anti-HCV and HCV RNA, who were 18 years of age and older were included in the study. Pretreatment baseline patient characteristics, treatment efficacy based on sustained virologic response (SVR) 12 weeks after treatment completion, and adverse effects were assessed. The following treatments were given according to the American Association for the Study of Liver Diseases\/Infectious Disease Society of America (AASLD\/IDSA) HCV Guidance: ledipasvir\/sofosbuvir, sofosbuvir plus weight-based ribavirin, and sofosbuvir\/velpatasvir.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 501 patients with a mean age of 54.3 (range 21.3\u201378.3) in the study. Overall SVR was achieved in 95.2% of patients who received one of the three DAA regimens. For those with cirrhosis, overall SVR was 92.8% and for those with genotype 3 91.1% achieved SVR. The most common symptom experienced during treatment was headache. Joint pain was found to decrease during treatment. One person discontinued sofosbuvir plus ribavirin due to myocardial infarction and one discontinued sofosbuvir\/velpatasvir due to urticaria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the real-world setting, sofosbuvir-based treatment is safe, effective, and well tolerated in AN\/AI patients. Sustained virologic response was high regardless of HCV genotype or cirrhosis status.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0260970","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T14:47:50Z","timestamp":1638456470000},"page":"e0260970","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Alaska Native\/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9497-3353","authenticated-orcid":true,"given":"Lisa","family":"Townshend-Bulson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Roik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youssef","family":"Barbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana J. T.","family":"Bruden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chriss E.","family":"Homan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah G. F.","family":"Espera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J.","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette M.","family":"Hewitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wileina","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Gove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia N.","family":"Plotnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary M.","family":"Snowball","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"McGilvray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenna C.","family":"Simons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8738-9677","authenticated-orcid":true,"given":"Janet M.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"issue":"2","key":"pone.0260970.ref001","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","article-title":"Evolving epidemiology of hepatitis C virus","volume":"17","author":"D. Lavanchy","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"pone.0260970.ref002","unstructured":"WHO. Global Hepatitis Report 2017 Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255016\/9789241565455-eng.pdf;jsessionid=57E13E6157F27DF0909272374DB84FAA?sequence=1."},{"issue":"26","key":"pone.0260970.ref003","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.4254\/wjh.v7.i26.2676","article-title":"Hepatitis C virus: A global view","volume":"7","author":"AA Mohamed","year":"2015","journal-title":"World J Hepatol"},{"key":"pone.0260970.ref004","unstructured":"CDC. Viral Hepatits Surveillance Report United States, 2019. 2019 Available from: https:\/\/www.cdc.gov\/hepatitis\/statistics\/2019surveillance\/index.htm."},{"issue":"6","key":"pone.0260970.ref005","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"HB El-Serag","year":"2012","journal-title":"Gastroenterology"},{"issue":"10159","key":"pone.0260970.ref006","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"GA Roth","year":"2018","journal-title":"The Lancet"},{"issue":"3","key":"pone.0260970.ref007","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.30297","article-title":"Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013\u20132016","volume":"69","author":"MG Hofmeister","year":"2019","journal-title":"Hepatology"},{"key":"pone.0260970.ref008","unstructured":"CDC. Liver cancer. Facts. 2019 Available from: https:\/\/www.cdc.gov\/cancer\/liver\/index.htm."},{"key":"pone.0260970.ref009","unstructured":"State of Alaska. Hepatitis C Overview and Treatment Update Anchorage, AK2019 Available from: http:\/\/www.epi.alaska.gov\/bulletins\/docs\/b2019_15.pdf."},{"key":"pone.0260970.ref010","unstructured":"HHS. National Viral Hepatitis Action Plan 2011. 2011 Available from: https:\/\/www.hhs.gov\/sites\/default\/files\/action-plan-viral-hepatitis-2011.pdf."},{"key":"pone.0260970.ref011","unstructured":"Department of Health WS. Plan to Eliminate Hepatitis C in Washington State by 2030 2019 Available from: https:\/\/www.doh.wa.gov\/Portals\/1\/Documents\/Pubs\/150nonDOH-HepCFreeWA-PlanJuly2019.pdf."},{"key":"pone.0260970.ref012","unstructured":"Department of Health NYS. New York State Hepatitis C Elimination Task Force 2019 Available from: https:\/\/www.health.ny.gov\/diseases\/communicable\/hepatitis\/hepatitis_c\/elimination.htm."},{"issue":"3","key":"pone.0260970.ref013","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1053\/j.gastro.2009.10.056","article-title":"Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection","volume":"138","author":"BJ McMahon","year":"2010","journal-title":"Gastroenterology"},{"key":"pone.0260970.ref014","article-title":"Cascade of Care for Alaska Native People with Chronic Hepatitis C Virus Infection: Statewide Program with High Linkage to Care","author":"BJ McMahon","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pone.0260970.ref015","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/hep.20046","article-title":"Epidemiology and risk factors for hepatitis C in Alaska Natives","volume":"39","author":"BJ McMahon","year":"2004","journal-title":"Hepatology"},{"issue":"3","key":"pone.0260970.ref016","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.cgh.2016.10.012","article-title":"Infection With Hepatitis C Virus Genotype 3 Is an Independent Risk Factor for End-Stage Liver Disease, Hepatocellular Carcinoma, and Liver-Related Death","volume":"15","author":"BJ McMahon","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"pone.0260970.ref017","doi-asserted-by":"crossref","first-page":"30696","DOI":"10.3402\/ijch.v75.30696","article-title":"Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C.","volume":"75","author":"SE Livingston","year":"2016","journal-title":"Int J Circumpolar Health."},{"issue":"1","key":"pone.0260970.ref018","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hep.29115","article-title":"Risk of end-stage liver disease, hepatocellular carcinoma, and liver-related death by fibrosis stage in the hepatitis C Alaska Cohort","volume":"66","author":"DJT Bruden","year":"2017","journal-title":"Hepatology"},{"key":"pone.0260970.ref019","unstructured":"HHS. National Viral Hepatitis Plan 2017\u20132020. 2017 Available from: https:\/\/www.hhs.gov\/hepatitis\/action-plan\/national-viral-hepatitis-action-plan-overview\/index.html."},{"issue":"1","key":"pone.0260970.ref020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1574887108666131213120354","article-title":"Efficacy and Safety of Sofosbuvir in the Treatment of Chronic Hepatitis C: The Dawn of a New Era.","volume":"9","author":"I Gentile","year":"2014","journal-title":"Rev Recent Clin Trials."},{"issue":"12","key":"pone.0260970.ref021","first-page":"815","article-title":"A Fixed-Dose Combination of Sofosbuvir and Ledipasvir for Hepatitis C Virus Genotype 1.","volume":"10","author":"NH Afdhal","year":"2014","journal-title":"Gastroenterol Hepatol (N Y)."},{"issue":"3","key":"pone.0260970.ref022","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/infdis\/jiv005","article-title":"Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes","volume":"212","author":"ZM Younossi","year":"2015","journal-title":"J Infect Dis"},{"key":"pone.0260970.ref023","unstructured":"WHO. Hepatitis C. Key Facts. 2019 [Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"issue":"2","key":"pone.0260970.ref024","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/hep.28901","article-title":"The association between race\/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection","volume":"65","author":"F Su","year":"2017","journal-title":"Hepatology"},{"issue":"7","key":"pone.0260970.ref025","doi-asserted-by":"crossref","first-page":"ofz128","DOI":"10.1093\/ofid\/ofz128","article-title":"Retrospective Study Demonstrating High Rates of Sustained Virologic Response After Treatment With Direct-Acting Antivirals Among American Indian\/Alaskan Natives.","volume":"6","author":"J Mera","year":"2019","journal-title":"Open Forum Infect Dis."},{"issue":"40","key":"pone.0260970.ref026","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.40.1700408","article-title":"Summary of available surveillance data on hepatitis C virus infection from eight Arctic countries, 2012 to 2014.","volume":"23","author":"PP Gounder","year":"2018","journal-title":"Euro Surveill."},{"key":"pone.0260970.ref027","unstructured":"American Association for the Study of Liver Diseases and Infectious Diseases Society of America. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C 2014\u20132018 [Available from: hcvguidelines.org."},{"key":"pone.0260970.ref028","unstructured":"AASLD. AASLD guidelines for treatment of chronic hepatitis B 2015 Available from: https:\/\/aasldpubs.onlinelibrary.wiley.com\/doi\/full\/10.1002\/hep.28156."},{"issue":"10","key":"pone.0260970.ref029","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1097\/MEG.0000000000001233","article-title":"Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study","volume":"30","author":"V Gayam","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"21","key":"pone.0260970.ref030","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","article-title":"Sofosbuvir and ribavirin in HCV genotypes 2 and 3","volume":"370","author":"S Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0260970.ref031","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1002\/hep.27724","article-title":"Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials","volume":"61","author":"ZM Younossi","year":"2015","journal-title":"Hepatology"},{"issue":"4","key":"pone.0260970.ref032","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1053\/j.gastro.2018.06.042","article-title":"Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.","volume":"155","author":"R Esteban","year":"2018","journal-title":"Gastroenterology"},{"issue":"4","key":"pone.0260970.ref033","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/jvh.12648","article-title":"Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort","volume":"24","author":"S Alonso","year":"2017","journal-title":"J Viral Hepat"},{"issue":"6","key":"pone.0260970.ref034","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/cid\/ciw387","article-title":"Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study","volume":"63","author":"JJ Feld","year":"2016","journal-title":"Clin Infect Dis"},{"key":"pone.0260970.ref035","article-title":"Hepatitis C cure improved patient-reported outcomes in patients with and without liver fibrosis in a prospective study at a large urban medical center","author":"JC Sung","year":"2019","journal-title":"J Viral Hepat"},{"issue":"16","key":"pone.0260970.ref036","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1097\/QAD.0000000000001966","article-title":"Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection","volume":"32","author":"GM Lledo","year":"2018","journal-title":"AIDS"},{"issue":"6","key":"pone.0260970.ref037","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.ultrasmedbio.2015.01.011","article-title":"Influence of Hepatic Inflammation on FibroScan Findings in Diagnosing Fibrosis in Patients with Chronic Hepatitis B","volume":"41","author":"X Zeng","year":"2015","journal-title":"Ultrasound Med Biol"},{"key":"pone.0260970.ref038","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcv.2017.05.021","article-title":"Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice.","volume":"93","author":"E Loggi","year":"2017","journal-title":"J Clin Virol"},{"issue":"4","key":"pone.0260970.ref039","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2019.11.012","article-title":"Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis","volume":"72","author":"B Hajarizadeh","year":"2020","journal-title":"Journal of hepatology"},{"issue":"4","key":"pone.0260970.ref040","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s11524-020-00422-0","article-title":"Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City.","volume":"98","author":"CN Behrends","year":"2021","journal-title":"Journal of urban health: bulletin of the New York Academy of Medicine"},{"issue":"1","key":"pone.0260970.ref041","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/10826084.2018.1485699","article-title":"Hepatitis C Testing, Status and Treatment among Marginalized People Who Use Drugs in an Inner City Setting: An Observational Cohort Study.","volume":"54","author":"LM Boucher","year":"2019","journal-title":"Substance Use & Misuse."},{"issue":"3","key":"pone.0260970.ref042","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/1060028014563952","article-title":"Ledipasvir-sofosbuvir: interferon-\/ribavirin-free regimen for chronic hepatitis C virus infection","volume":"49","author":"MA Smith","year":"2015","journal-title":"The Annals of pharmacotherapy"},{"issue":"27","key":"pone.0260970.ref043","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection","volume":"373","author":"JJ Feld","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0260970.ref044","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","article-title":"Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial","volume":"15","author":"M Mizokami","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"pone.0260970.ref045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12879-015-0748-8","article-title":"Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits.","volume":"15","author":"J Smith-Palmer","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"3","key":"pone.0260970.ref046","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2893.2011.01563.x","article-title":"Economic burden of hepatitis C-associated diseases in the United States","volume":"19","author":"AC El Khoury","year":"2012","journal-title":"J Viral Hepat"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0260970","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T14:48:41Z","timestamp":1638456521000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0260970"}},"subtitle":[],"editor":[{"given":"Kimberly","family":"Page","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":46,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,12,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0260970","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.09.03.21263089","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]}}}